The skyrocketing demand for telemedicine and expansion of reimbursement for telehealth visits due to COVID-19 is likely going to shift the paradigm for diabetes care delivery into the future, setting up diabetes software company Glooko, Inc. for continued growth.
When the first shelter-in-place regulations kept diabetes patients from seeing their doctors in the office due to the pandemic, the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?